Baird Initiates Coverage On Alto Neuroscience with Outperform Rating, Announces Price Target of $32
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Brian Skorney initiates coverage on Alto Neuroscience (NYSE:ANRO) with an Outperform rating and a price target of $32.
February 27, 2024 | 10:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Brian Skorney has initiated coverage on Alto Neuroscience with an Outperform rating and a price target of $32.
The initiation of coverage by Baird with an Outperform rating and a significant price target suggests a positive outlook for ANRO's stock in the short term. This endorsement from a reputable analyst could lead to increased investor interest and potentially drive the stock price up as the market reacts to the new coverage and price target.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100